Immunotherapy of malignancy in humans. Current status
E. C. Holmes, F. R. Eilber and D. L. Morton
Many observations support the premise of a close relationship between
immunologic competency and the growth of human cancer. Immunotherapy
against cancer in animals has been established. Its function appears to be
adjunctive to other treatment modalities that first lower tumor burden.
These findings are demonstrated in both clinical and laboratory studies of
cancer in humans. At the present time, intralesional injections of BCG
vaccine in immunocompetent patients with intradermal metastases are most
effective. Immunotherapy with topical administration of 2,4
dinitrochlorobenzene is the treatment of choice in selected patients with
squamous or basal cell carcinoma.
